{"id":26608,"date":"2024-11-21T12:04:11","date_gmt":"2024-11-21T11:04:11","guid":{"rendered":"https:\/\/idibell.cat\/?page_id=26608"},"modified":"2024-12-13T11:13:30","modified_gmt":"2024-12-13T10:13:30","slug":"quimica-medica-i-disseny-de-farmacs","status":"publish","type":"page","link":"https:\/\/idibell.cat\/recerca\/area-de-cancer\/programa-de-mecanismes-moleculars-i-terapia-experimental-en-oncologia-oncobell\/quimica-medica-i-disseny-de-farmacs\/","title":{"rendered":"Qu\u00edmica M\u00e8dica i Disseny de F\u00e0rmacs"},"content":{"rendered":"\n<h1>\n\t\tQu\u00edmica m\u00e8dica i disseny de f\u00e0rmacs\n\t<\/h1>\n<h3>\n\t\tResum\n\t<\/h3>\n\t<p>El grup de recerca en qu\u00edmica medica i disseny de f\u00e0rmacs \u00e9s un grup computacional i experimental que fa servir eines de qu\u00edmica org\u00e0nica, biologia, i ci\u00e8ncia de dades per entendre millor el mecanisme d&#8217;acci\u00f3 dels f\u00e0rmacs per fer-los servir de forma m\u00e9s eficient en medicina de precisi\u00f3 i dissenyar nous f\u00e0rmacs m\u00e9s segurs i efica\u00e7os per al tractament del c\u00e0ncer.\u00a0 El grup tamb\u00e9 col\u00b7labora activament en iniciatives internacionals de ci\u00e8ncia oberta en qu\u00edmica biol\u00f2gica centrades en la recopilaci\u00f3, estandarditzaci\u00f3, i accessibilitat de Big Data. Finalment, tamb\u00e9 desenvola les seves pr\u00f2pies eines d&#8217;intel\u00b7lig\u00e8ncia artificial per accelerar el descobriment de f\u00e0rmacs.<\/p>\n<h3> 33<\/h3>\n<h2>Publicacions<\/h2>\n\t\t\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/idibell.cat\/wp-content\/uploads\/2024\/11\/Medicinal-chemistry-drug-design.jpg\" alt=\"Medicinal-chemistry-&amp;-drug-design\" itemprop=\"image\" height=\"300\" width=\"600\" title=\"Medicinal-chemistry-&amp;-drug-design\" onerror=\"this.style.display='none'\"  \/>\n\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--label-0\" tabindex=\"0\" aria-controls=\"fl-accordion--panel-0\">L\u00ednies estrat\u00e8giques<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--icon-0\" tabindex=\"-1\"><i title=\"Expand\">Expand<\/i><\/a>\n\t\t\t\t\t<ul>\n<li>Desenvolupar recursos de biologia qu\u00edmica de ci\u00e8ncia oberta.<\/li>\n<li>Aprofitar els efectes dels f\u00e0rmacs a nivell de sistemes en medicina de precisi\u00f3.<\/li>\n<li>Explotar el Big Data i la IA per descobrir f\u00e0rmacs m\u00e9s efica\u00e7os.<\/li>\n<\/ul>\n\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--label-1\" tabindex=\"0\" aria-controls=\"fl-accordion--panel-1\">Publicacions seleccionades<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--icon-1\" tabindex=\"-1\"><i title=\"Expand\">Expand<\/i><\/a>\n\t\t\t\t\t<ul>\n<li>Manen-Freixa L, *Antolin AA. <strong>Polypharmacology prediction: the long road toward comprehensively anticipating small-molecule selectivity to de-risk drug discovery. Expert Opin Drug Discov<\/strong>. 19, 1043-1069 (2024).<\/li>\n<li>Hu H, Serra C, Zhang W, Scrivo A, Fernandez-Carasa I, Consiglio A, Aytes A, Pujana MA, *Llebaria A, *Antolin AA. <strong>Identification of differential biological activity and synergy between the PARP inhibitor rucaparib and its major metabolite<\/strong>. Cell Chemical Biology, 31, 973-988 (2024).<\/li>\n<li>di Micco,+ Antolin AA,+ Mitsopoulos C, Villasclaras Fernandez E, Mica IL, et al. <strong>canSAR: update to the cancer translational research and drug discovery knowledgebase<\/strong>. Nucleic Acids Res. 51, D1212-D1219 (2023).<\/li>\n<li>Antolin AA, Sanfelice D, Crisp A, Villasclaras Fernandez E, Mica IL, et al. <strong>The Chemical Probes Portal: an expert review based public resource to empower chemical probe assessment, selection and use<\/strong>. Nucleic Acids Res. 51, D1492-D1502 (2023).<\/li>\n<li>Hu H, Tjaden A, Knapp S, *Antolin AA, *M\u00fcller S. <strong>A machine learning and live-cell imaging tool kit uncovers small molecules induced phospholipidosis<\/strong>. Cell Chem Biol. 30, 1634-1651(2023).<\/li>\n<\/ul>\n\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--label-2\" tabindex=\"0\" aria-controls=\"fl-accordion--panel-2\">Projectes seleccionats<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--icon-2\" tabindex=\"-1\"><i title=\"Expand\">Expand<\/i><\/a>\n\t\t\t\t\t<ul>\n<li><strong>Systems-based Characterization of Drug Metabolites to Exploit them in Precision medicine<\/strong>. Agency: Spanish Ministry of Economy (MINECO) &#8211; Plan Nacional. IP: Dr. Albert Antolin. 2023-2026. Amount: 130.000 \u20ac.<\/li>\n<li><strong>Systems Drug Discovery to Tackle Cancer Drug Resistance<\/strong>. Agency: Instituto de Salud Carlos III (ISCIII) &#8211; Miguel Servet Fellowship. IP: Dr. Albert Antolin. 2023 &#8211; 2028. Amount: 240.000 \u20ac.<\/li>\n<li><strong>Rational development of KRAS inhibitors that simultaneously inhibit kinases<\/strong>. Agency: VIVAN Therapeutics (London, UK) &#8211; industrial collaboration. IP: Dr. Albert Antolin (coordinator), Prof. Paul Workman (ICR) and Dr. Nahuel Villegas (VIVAN). 2023 &#8211; June 2024. Amount: 50.000 \u00a3<\/li>\n<li><strong>Systems Drug Discovery to Tackle Cancer Drug Resistance<\/strong>. Agency: La Caixa Foundation. IP: Dr. Albert Antolin. 2022 &#8211; 2023. Amount: 300.000 \u20ac.<\/li>\n<\/ul>\n\t\t\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/01\/Albert-Antolin-Hernandez-150x150.jpg\" alt=\"Albert-Antolin-Hernandez\" itemprop=\"image\" height=\"150\" width=\"150\" title=\"Albert-Antolin-Hernandez\" onerror=\"this.style.display='none'\"  \/>\n<h4>\n\t\tAntolin Hernandez, Albert\n\t<\/h4>\n<h4>\n\t\t<a href=\"mailto:aantolin@idibell.cat\" title=\"aantolin@idibell.cat\" target=\"_blank\" rel=\"noopener\">\n\t\taantolin@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n<h2>\n\t\tInvestigadors principals\n\t<\/h2>\n\t\t\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/01\/Albert-Antolin-Hernandez-150x150.jpg\" alt=\"Albert-Antolin-Hernandez\" itemprop=\"image\" height=\"150\" width=\"150\" title=\"Albert-Antolin-Hernandez\" onerror=\"this.style.display='none'\"  \/>\n<h4>\n\t\tAntolin Hernandez, Albert\n\t<\/h4>\n<h4>\n\t\t<a href=\"mailto:aantolin@idibell.cat\" title=\"aantolin@idibell.cat\" target=\"_blank\" rel=\"noopener\">\n\t\taantolin@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n<h4>\n\t\tENLLA\u00c7OS RELACIONATS\n\t<\/h4>\n<h4>\n\t\t<a href=\"https:\/\/procure-oncology.com\/portfolio-item\/antolins-lab\/\" title=\"ProCURE\" target=\"_blank\" rel=\"noopener\">\n\t\tProCURE\n\t\t<\/a>\n\t<\/h4>\n<h4>\n\t\t<a href=\"https:\/\/twitter.com\/antolin_aa\" title=\"@antolin_aa\" target=\"_blank\" rel=\"noopener\">\n\t\t@antolin_aa\n\t\t<\/a>\n\t<\/h4>\n<h4>\n\t\t<a href=\"https:\/\/twitter.com\/ProcureICO\" title=\"@ProcureICO\" target=\"_blank\" rel=\"noopener\">\n\t\t@ProcureICO\n\t\t<\/a>\n\t<\/h4>\n<h4>\n\t\t<a href=\"https:\/\/www.chemicalprobes.org\/people\" title=\"Chemical Probes Portal\" target=\"_blank\" rel=\"noopener\">\n\t\tChemical Probes Portal\n\t\t<\/a>\n\t<\/h4>\n<h4>\n\t\t<a href=\"https:\/\/aircheck.ai\/mainframe\" title=\"MAINFRAME\" target=\"_blank\" rel=\"noopener\">\n\t\tMAINFRAME\n\t\t<\/a>\n\t<\/h4>\n<h2>\n\t\tEquip\n\t<\/h2>\n\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-tabs--label-0\" data-index=\"0\" aria-selected=\"true\" aria-controls=\"fl-tabs--panel-0\" aria-expanded=\"true\" role=\"tab\" tabindex=\"0\">\t\t\t\tCaps de grup\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-tabs--label-1\" data-index=\"1\" aria-selected=\"false\" aria-controls=\"fl-tabs--panel-1\" aria-expanded=\"false\" role=\"tab\" tabindex=\"0\">\t\t\t\tInvestigadors\/es postdoctorals\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-tabs--label-2\" data-index=\"2\" aria-selected=\"false\" aria-controls=\"fl-tabs--panel-2\" aria-expanded=\"false\" role=\"tab\" tabindex=\"0\">\t\t\t\tInvestigadors\/es predoctorals\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-tabs--label-3\" data-index=\"3\" aria-selected=\"false\" aria-controls=\"fl-tabs--panel-3\" aria-expanded=\"false\" role=\"tab\" tabindex=\"0\">\t\t\t\tSuport cient\u00edfic\t\t\t\t<\/a>\n\t\t\t\t\t\tCaps de grup\n\t\t\t\t\t\t\t\t\t\t\t<ul>\n<li>Antolin Hernandez, Albert<\/li>\n<\/ul>\n\t\t\t\t\t\tInvestigadors\/es postdoctorals\n\t\t\t\t\t\t\t\t\t\t\t<ul>\n<li>Manen Freixa, Leticia<\/li>\n<\/ul>\n\t\t\t\t\t\tInvestigadors\/es predoctorals\n\t\t\t\t\t\t\t\t\t\t\t<ul>\n<li>Ruvo, Luca<\/li>\n<\/ul>\n\t\t\t\t\t\tSuport cient\u00edfic\n\t\t\t\t\t\t\t\t\t\t\t<ul>\n<li>Santos Gil, Santiago<\/li>\n<\/ul>\n<h2>\n\t\tNot\u00edcies relacionades\n\t<\/h2>\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/26278\" content=\"Els aven\u00e7os en biologia qu\u00edmica requereixen multidisciplinarietat i treball en equip\" \/><meta itemprop=\"datePublished\" content=\"2024-09-20\" \/><meta itemprop=\"dateModified\" content=\"2024-11-21\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/03\/cropped-Marca-B.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/author\/comunicacio\/\" \/><meta itemprop=\"name\" content=\"comunicacio\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2024\/09\/cover.tif-1.jpg\" \/><meta itemprop=\"width\" content=\"591\" \/><meta itemprop=\"height\" content=\"768\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/2024\/09\/els-avencos-en-biologia-quimica-requereixen-multidisciplinarietat-i-treball-en-equip\/\" title=\"Els aven\u00e7os en biologia qu\u00edmica requereixen multidisciplinarietat i treball en equip\"><\/a>\n\t\t\t\t<h6 itemprop=\"headline\">\n\t\t\t<a href=\"https:\/\/idibell.cat\/2024\/09\/els-avencos-en-biologia-quimica-requereixen-multidisciplinarietat-i-treball-en-equip\/\" title=\"Els aven\u00e7os en biologia qu\u00edmica requereixen multidisciplinarietat i treball en equip\">Els aven\u00e7os en biologia qu\u00edmica requereixen multidisciplinarietat i treball en equip<\/a>\n\t\t<\/h6>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/author\/comunicacio\/\">comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t20\/09\/2024\t\t\t\t\t\t\t\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/25452\" content=\"La reutilitzaci\u00f3 de medicaments: noves oportunitats per als pacients oncol\u00f2gics\" \/><meta itemprop=\"datePublished\" content=\"2024-04-19\" \/><meta itemprop=\"dateModified\" content=\"2024-11-21\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/03\/cropped-Marca-B.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/author\/comunicacio\/\" \/><meta itemprop=\"name\" content=\"comunicacio\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2024\/04\/Albert-Antolin-Repurposing.jpg\" \/><meta itemprop=\"width\" content=\"1366\" \/><meta itemprop=\"height\" content=\"768\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/2024\/04\/la-reutilitzacio-de-medicaments-noves-oportunitats-per-als-pacients-oncologics\/\" title=\"La reutilitzaci\u00f3 de medicaments: noves oportunitats per als pacients oncol\u00f2gics\"><\/a>\n\t\t\t\t<h6 itemprop=\"headline\">\n\t\t\t<a href=\"https:\/\/idibell.cat\/2024\/04\/la-reutilitzacio-de-medicaments-noves-oportunitats-per-als-pacients-oncologics\/\" title=\"La reutilitzaci\u00f3 de medicaments: noves oportunitats per als pacients oncol\u00f2gics\">La reutilitzaci\u00f3 de medicaments: noves oportunitats per als pacients oncol\u00f2gics<\/a>\n\t\t<\/h6>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/author\/comunicacio\/\">comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t19\/04\/2024\t\t\t\t\t\t\t\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/25008\" content=\"Un f\u00e0rmac anticancer\u00f3s obre una nova via de tractament del Parkinson\" \/><meta itemprop=\"datePublished\" content=\"2024-02-09\" \/><meta itemprop=\"dateModified\" content=\"2024-11-21\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/03\/cropped-Marca-B.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/author\/comunicacio\/\" \/><meta itemprop=\"name\" content=\"comunicacio\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2024\/02\/Albert-Antolin.jpg\" \/><meta itemprop=\"width\" content=\"1366\" \/><meta itemprop=\"height\" content=\"768\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/2024\/02\/un-farmac-anticanceros-obre-una-nova-via-de-tractament-del-parkinson\/\" title=\"Un f\u00e0rmac anticancer\u00f3s obre una nova via de tractament del Parkinson\"><\/a>\n\t\t\t\t<h6 itemprop=\"headline\">\n\t\t\t<a href=\"https:\/\/idibell.cat\/2024\/02\/un-farmac-anticanceros-obre-una-nova-via-de-tractament-del-parkinson\/\" title=\"Un f\u00e0rmac anticancer\u00f3s obre una nova via de tractament del Parkinson\">Un f\u00e0rmac anticancer\u00f3s obre una nova via de tractament del Parkinson<\/a>\n\t\t<\/h6>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/author\/comunicacio\/\">comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t09\/02\/2024\t\t\t\t\t\t\t\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/24005\" content=\"Nou acord de col\u00b7laboraci\u00f3 amb l'ICR i Vivan Therapeutics per dissenyar nous tractaments personalitzats contra el c\u00e0ncer\" \/><meta itemprop=\"datePublished\" content=\"2023-07-13\" \/><meta itemprop=\"dateModified\" content=\"2024-11-21\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/03\/cropped-Marca-B.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/author\/comunicacio\/\" \/><meta itemprop=\"name\" content=\"comunicacio\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/07\/NO062-A-Antolin_Vivan-Tx-Imatge-noti.jpg\" \/><meta itemprop=\"width\" content=\"1366\" \/><meta itemprop=\"height\" content=\"768\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/2023\/07\/nou-acord-de-collaboracio-amb-licr-i-vivan-therapeutics-per-dissenyar-nous-tractaments-personalitzats-contra-el-cancer\/\" title=\"Nou acord de col\u00b7laboraci\u00f3 amb l'ICR i Vivan Therapeutics per dissenyar nous tractaments personalitzats contra el c\u00e0ncer\"><\/a>\n\t\t\t\t<h6 itemprop=\"headline\">\n\t\t\t<a href=\"https:\/\/idibell.cat\/2023\/07\/nou-acord-de-collaboracio-amb-licr-i-vivan-therapeutics-per-dissenyar-nous-tractaments-personalitzats-contra-el-cancer\/\" title=\"Nou acord de col\u00b7laboraci\u00f3 amb l'ICR i Vivan Therapeutics per dissenyar nous tractaments personalitzats contra el c\u00e0ncer\">Nou acord de col\u00b7laboraci\u00f3 amb l&#8217;ICR i Vivan Therapeutics per dissenyar nous tractaments personalitzats contra el c\u00e0ncer<\/a>\n\t\t<\/h6>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/author\/comunicacio\/\">comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t13\/07\/2023\t\t\t\t\t\t\t\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/23398\" content=\"Una ajuda de la Fundaci\u00f3 \"la Caixa\" permet a Albert Antol\u00edn instal\u00b7lar la seva recerca a l'IDIBELL\" \/><meta itemprop=\"datePublished\" content=\"2023-03-23\" \/><meta itemprop=\"dateModified\" content=\"2024-11-21\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/03\/cropped-Marca-B.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/author\/comunicacio\/\" \/><meta itemprop=\"name\" content=\"comunicacio\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/03\/NO036-A-Antolin_La-Caixa-Imatge-noti.jpg\" \/><meta itemprop=\"width\" content=\"1366\" \/><meta itemprop=\"height\" content=\"768\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/2023\/03\/una-ajuda-de-la-fundacio-la-caixa-permet-a-albert-antolin-installar-la-seva-recerca-a-lidibell\/\" title=\"Una ajuda de la Fundaci\u00f3 \"la Caixa\" permet a Albert Antol\u00edn instal\u00b7lar la seva recerca a l'IDIBELL\"><\/a>\n\t\t\t\t<h6 itemprop=\"headline\">\n\t\t\t<a href=\"https:\/\/idibell.cat\/2023\/03\/una-ajuda-de-la-fundacio-la-caixa-permet-a-albert-antolin-installar-la-seva-recerca-a-lidibell\/\" title=\"Una ajuda de la Fundaci\u00f3 \"la Caixa\" permet a Albert Antol\u00edn instal\u00b7lar la seva recerca a l'IDIBELL\">Una ajuda de la Fundaci\u00f3 &#8220;la Caixa&#8221; permet a Albert Antol\u00edn instal\u00b7lar la seva recerca a l&#8217;IDIBELL<\/a>\n\t\t<\/h6>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/author\/comunicacio\/\">comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t23\/03\/2023\t\t\t\t\t\t\t\n\t\t<!-- .pp-content-posts -->\n\n","protected":false},"excerpt":{"rendered":"<p>Qu\u00edmica m\u00e8dica i disseny de f\u00e0rmacs Resum El grup de recerca en qu\u00edmica medica i disseny de f\u00e0rmacs \u00e9s un grup computacional i experimental que fa servir eines de qu\u00edmica org\u00e0nica, biologia, i ci\u00e8ncia de dades per entendre millor el mecanisme d&#8217;acci\u00f3 dels f\u00e0rmacs per fer-los servir de forma m\u00e9s eficient en medicina de precisi\u00f3 [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":0,"parent":448,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"full-width-container","site-content-style":"unboxed","site-sidebar-style":"unboxed","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"class_list":["post-26608","page","type-page","status-publish","hentry"],"publishpress_future_action":{"enabled":false,"date":"2025-03-01 10:48:31","action":"change-status","newStatus":"draft","terms":[],"taxonomy":""},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/26608","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=26608"}],"version-history":[{"count":18,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/26608\/revisions"}],"predecessor-version":[{"id":26769,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/26608\/revisions\/26769"}],"up":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/448"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=26608"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}